IPO News | Deshi Biotech's Hong Kong stock IPO and “full circulation” of domestic unlisted shares were registered by the China Securities Regulatory Commission

The Zhitong Finance App learned that on January 5, the International Cooperation Department of the China Securities Regulatory Commission issued the “Notice on the “Full Circulation” of Overseas Issuance and Domestic Unlisted Shares of Hangzhou Deshi Biotechnology Co., Ltd. Deshi Biotech plans to issue no more than 31.04 million overseas listed common shares and list them on the Hong Kong Stock Exchange. The company's 27 shareholders intend to convert a total of 80.88 million domestic unlisted shares into overseas listed shares and list them for circulation on the Hong Kong Stock Exchange.

According to the prospectus, Deshi Biotech has always focused on the medical imaging AI industry. The company's proprietary iMediMageTM has a cross-modal pre-training architecture, enabling a single unified model to support 19 medical imaging modes (such as chromosomal, CT, MRI, ultrasound and pathology) and cover more than 90% of clinical medical imaging scenarios, including reproductive health, hematologic malignancies, and radiation health.

According to Frost & Sullivan data, iMedimageTM, independently developed by Desch Biotech, is a general-purpose medical imaging pedestal model with the largest parameters in the world. It has been successfully commercialized, and has been recognized as the world's first commercialized cross-modal medical imaging pedestal model.

Attachment: Names of “Fully Circulated” Shareholders and Number of Conversions